Pharma Companies Invest Billions in Protein-Degrader Drugs

The article describes pharmaceutical companies' investment in protein-degrader drugs, a class designed to target disease-related proteins in cells. It recounts one cancer patient's remission after joining a study, without identifying the drug or establishing a broader treatment outcome.